Adial Pharmaceuticals Inc
$ 2.98
0.00%
12 Jun - close price
- Market Cap 6,521,600 USD
- Current Price $ 2.98
- High / Low $ 3.14 / 2.52
- Stock P/E N/A
- Book Value 2.46
- EPS -4.89
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.11 %
- ROE -2.66 %
- 52 Week High 18.90
- 52 Week Low 1.31
About
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for the treatment or prevention of addictions and related disorders. The company is headquartered in Charlottesville, Virginia.
Analyst Target Price
$8.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-08 | 2026-03-10 | 2025-11-13 | 2025-08-13 | 2025-05-14 | 2025-03-04 | 2024-11-13 | 2024-08-13 | 2024-04-04 | 2024-02-20 | 2023-11-14 | 2023-08-21 |
| Reported EPS | -1.48 | -11.48 | -0.08 | -0.18 | -0.34 | -0.15 | -0.38 | -0.59 | -0.62 | -1.35 | -1.18 | 0.96 |
| Estimated EPS | -2.25 | -2.13 | -0.39 | -0.39 | -0.495 | -0.33 | -0.44 | -0.53 | -0.33 | -0.76 | -1.13 | -1.5 |
| Surprise | 0.77 | -9.35 | 0.31 | 0.21 | 0.155 | 0.18 | 0.06 | -0.06 | -0.29 | -0.59 | -0.05 | 2.46 |
| Surprise Percentage | 34.2222% | -438.9671% | 79.4872% | 53.8462% | 31.3131% | 54.5455% | 13.6364% | -11.3208% | -87.8788% | -77.6316% | -4.4248% | 164% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADIL
2026-06-12 20:38:36
This article lists several healthcare stocks that experienced significant movement in Friday's after-market session. Gainers include Aspire Biopharma Holdings, Innate Pharma, Aditxt, Retractable Technologies, Aytu BioPharma, and XORTX Therapeutics. Losers include Cuprina Holdings (Cayman), Zhengye Biotechnology, Adial Pharmaceuticals, Autonomix Medical, Theriva Biologics, and GlucoTrack.
2026-06-12 12:05:54
This article lists 12 healthcare stocks experiencing significant movement in Friday's pre-market session, categorized into gainers and losers. Notable movers include Aditxt (ADTX) and Eikon Therapeutics (EIKN) with significant gains, while Gelteq (GELS) and MBX Biosciences (MBX) saw considerable declines. The article provides the percentage change and current price for each stock, along with their respective market capitalization.
2026-06-12 11:49:00
Adial Pharmaceuticals has acquired Azora Therapeutics for $32 million, gaining Azora’s lead asset AT177, an oral treatment for ulcerative colitis. Concurrently, Adial secured up to $64 million in financing, with an initial $32 million, led by Coastlands Capital. The proceeds will fund clinical studies for AT177, with Phase 1 initiation planned for mid-2027, and the acquisition restructured ownership with former Azora equity holders owning 51.0% of the combined company.
2026-06-11 21:09:40
This article lists several healthcare stocks that experienced significant movement during Thursday's after-market trading session. It highlights both gainers, such as Rocket One and Stablecoin Development, and losers, including Gelteq and VolitionRX, providing their percentage changes and market capitalizations. The information presented is generated by Benzinga's automated content engine and reviewed by an editor.
2026-06-11 19:09:41
Adial Pharmaceuticals (ADIL) has acquired Azora Therapeutics, gaining the lead asset AT177 for inflammatory diseases. The acquisition is backed by a $64 million private placement, with $32 million immediately available and the remainder contingent on Phase 1 trial initiation for AT177 in ulcerative colitis. The company also appointed Wendy Young, Ph.D., to its Board of Directors, as it navigates a critical development phase despite a low GF Score™ indicating profitability challenges.
2026-06-11 18:09:41
Adial Pharmaceuticals has announced the acquisition of Azora Therapeutics, along with securing financing of up to $64 million. This strategic move is expected to bolster Adial Pharmaceuticals' operations and therapeutic development pipeline.
